Paper - WANFANG MED ONLINE

You Position: Home > Paper

Comparison of Clinical Features between Pyoderma Gangrenosum Concomitant by Inflammatory Bowel Disease and Idiopathic Pyoderma Gangrenosum

( views:20, downloads:8 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 22

DOI:: 10.4103/0366-6999.218004

Key Word:: Crohn Disease;Idiopathic;Pyoderma Gangrenosum;Ulcerative Colitis

Abstract： Background:Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that is highly associated with inflammatory bowel disease (IBD).Certain PG patients with no systemic disorders have been diagnosed with idiopathic PG.This study sought to clarify the difference between PG with IBD and idiopathic PG based on clinical features,laboratory tests,and medications.Methods:Twelve patients with PG and IBD and 24 patients with idiopathic PG,who were hospitalized in Peking Union Medical College Hospital from 2000 to 2017,were retrospectively categorized into the IBD group and control group,respectively.Data of clinical features,laboratory tests,and medications were collected and compared between the two groups.Results:Both groups were similar with respect to their clinical features.However,the IBD group had an increased occurrence ofarthralgia or arthritis (58.3％ vs.12.5％,P =0.007),anemia (83.3％ and 29.2％,P =0.004),and an increased percentage of antineutrophilic cytoplasmic antibody (ANCA)-positive patients (85.7％ and 0.0％,P ＜ 0.001),compared to the control group.Conclusion:PG patients with IBD had increased occurrence rates ofarthralgia or arthritis,anemia,and ANCA-positive status compared to idiopathic PG patients.

Reference

[1]Susanna Nikolaus,Stefan Schreiber.Diagnostics of Inflammatory Bowel Disease[J].2007,133(5).
[2]Philipp, Al Ghazal,Katharina, Herberger,J?rg, Schaller,etc.Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients.[J].2013,8(1).
[3]Harbord, Marcus,Annese, Vito,Vavricka, Stephan R.,etc.The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease[J].2016,10(3).
[4]Forum, Patel,Sarah, Fitzmaurice,Christopher, Duong,etc.Effective strategies for the management of pyoderma gangrenosum: a comprehensive review.[J].2015,95.
[5]J P, Callen.Pyoderma gangrenosum.[J].1998,351(9102).
[6]Shinkai,K.,Ahronowitz,I.,Harp,J..Etiology and management of pyoderma gangrenosum: A comprehensive review[J].2012,13(3).
[7].Cutaneous manifestations in patients with inflammatory bowel diseases: Pathophysiology, clinical features, and therapy[J].2014,20(1).
[8]Biedermann T,Hoerber S,Fehrenbacher B,etc.Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.[J].2011,147(10).
[9]P, von den Driesch.Pyoderma gangrenosum: a report of 44 cases with follow-up.[J].1997,137(6).
[10]Yang, Hong,Li, Yumei,Wu, Wei,etc.The Incidence of Inflammatory Bowel Disease in Northern China: A Prospective Population-Based Study.[J].2014,9(7).
[11]Adam V, Weizman,Brian, Huang,Stephan, Targan,etc.Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study.[J].2014,18.
[12]S, Bhagat,K M, Das.A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody.[J].1994,107.
[13]Qureshi AA,Winterfield LS,Li VW,etc.Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients.[J].2011,165(6).
[14]Jörg Reichrath,Guido Bens,Anette Bonowitz,etc.Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients[J].2005,53(2).
[15]Argüelles-Arias,F.,Castro-Laria,L.,Lobatón,T.,etc.Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease[J].2013,58(10).
[16]Frank C Powell,W.P Daniel Su,Harold O Perry.Pyoderma gangrenosum: Classification and management[J].1996,34(3).
[17]Margit Polcz,Jennie Gu,Timothy Florin.Pyoderma gangrenosum in inflammatory bowel disease: The experience at Mater Health Services Adult Hospital 1998-2009[J].2011,5(2).
[18]C, Feliciani,C, De Simone,P, Amerio.Dermatological signs during inflammatory bowel diseases.[J].2009,13 Suppl 1.
[19]Helm KF,Miller JJ,Nguyen KH.Case reports and a review of the literature on ulcers mimicking pyoderma gangrenosum.[J].2003,42(2).
[20]Ana, Gameiro,Neide, Pereira,José Carlos, Cardoso,etc.Pyoderma gangrenosum: challenges and solutions.[J].2015,8.
[21]Hoffman MD.Pyoderma gangrenosum associated with c-ANCA (h-lamp-2).[J].2001,40(2).
[22]Shu chen Wei,Richard B Gearry,Khoon Lin Ling,etc.The Asia-Pacific consensus on ulcerative colitis[J].2010,25(3).
[23]Marzano AV,Cugno M,Trevisan V,etc.Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases.[J].2010,162(1).
[24]Brun L,Rogler G,Ballabeni P,etc.Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.[J].2011,106(1).
[25]Okhovat,J.-P.,Shinkai,K..Pyoderma gangrenosum[J].2014,150(9).
[26]Adam, Weizman,Brian, Huang,Dror, Berel,etc.Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.[J].2014,20.